Castration-Resistant Prostate Cancer: AUA Guideline

This is a clinical practice guideline for patients with castration-resistant prostate cancer (CRPC). The guideline provides recommendations on different patient types, with consideration to whether patient is symptomatic/asymptomatic, if cancer is metastatic, poor vs good performance status, and whether or not patient has previously received docetaxel chemotherapy. Outcomes of interest include survival (overall survival, progression-free, metastasis-free) PSA PFS, PSA decline, measurable disease response, adverse events/side-effects of treatment, quality of life (QOL), skeletal-related events (SREs), pain-free survival, and pain response.